The co‐treatment of curucmin with cisplatin improved markers of mitochondrial biogenesis (PGC‐1α, TFAM) and suppressed ET‐1‐mediated renal fibrosis and apoptosis. It also suppressed ET‐1 expression, activated ETBR, enhanced NRF2 expression, inhibited renal injury, preserved kidney function, and regulated the ET‐1/ETBR/ETAR signaling pathway. The gene discussed is EDNRA; the disease is renal fibrosis.